RNTX 8-K Update (Nov 3, 2025)
Material Clinical Event: Rein Therapeutics received FDA clearance to resume its U.S. Phase 2 Trial for LTI-03.
- Indication: Idiopathic Pulmonary Fibrosis (IPF).
This clearance is a critical step, enabling the progression of the company’s lead therapeutic candidate through clinical development.
- Registrant: REIN THERAPEUTICS, INC. (RNTX)
- Executive Signatory: Brian Windsor, Ph.D. (CEO)
No new financial metrics or specific risk factors detailed in this filing, which focuses solely on the regulatory update.